Mortality rates among individuals diagnosed with hepatitis C virus (HCV); an observational cohort study, England, 2008 to 2016

BackgroundMonitoring trends in mortality for individuals diagnosed with hepatitis C virus (HCV) infection are important as we expand treatment and move towards World Health Organization elimination targets.AimTo estimate mortality rates for individuals aged ≥ 15 years diagnosed with HCV infection in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Euro surveillance : bulletin européen sur les maladies transmissibles 2019-07, Vol.24 (30)
Hauptverfasser: Ireland, Georgina, Mandal, Sema, Hickman, Matthew, Ramsay, Mary, Harris, Ross, Simmons, Ruth
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 30
container_start_page
container_title Euro surveillance : bulletin européen sur les maladies transmissibles
container_volume 24
creator Ireland, Georgina
Mandal, Sema
Hickman, Matthew
Ramsay, Mary
Harris, Ross
Simmons, Ruth
description BackgroundMonitoring trends in mortality for individuals diagnosed with hepatitis C virus (HCV) infection are important as we expand treatment and move towards World Health Organization elimination targets.AimTo estimate mortality rates for individuals aged ≥ 15 years diagnosed with HCV infection in England 2008-16.MethodsAn observational cohort study whereby death certificate information was linked to the Sentinel Surveillance of Blood Borne Virus Testing in England. Age-sex standardised mortality rates (ASMR) for individuals diagnosed with HCV infection (2008-16) were calculated and compared to the general population.ResultsOf 43,895 individuals with HCV infection, 2,656 (6.3%) died. All-cause ASMRs were 2,834.2 per 100,000 person years (PY), 2.3 times higher than in the general population. In individuals aged 30-69 years, all-cause mortality rates were 1,768.9 per 100,000 PY among individuals with HCV, 4.7 times higher than in the general population. ASMRs had not decreased between 2010 (2,992) and 2016 (2,340; p=0.10), with no change from 2014 (p = 0.058). ASMRs were 441.0 times higher for hepatitis, 34.4 times higher for liver cancer, 8.1 times higher for end stage liver disease and 6.4 times higher for external causes than in the general population.ConclusionsMortality was higher in individuals with diagnosed HCV infection compared to the general population, highlighting health inequalities. There is a need to improve HCV diagnosis, engagement in care and treatment rates. The high mortality from external causes highlights the importance of integrated health and social care strategies and addressing the needs of this vulnerable population.
doi_str_mv 10.2807/1560-7917.ES.2019.24.30.1800695
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6668288</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>31362807</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-14b436c0b698ded396db00ec41ba6370554c8f7cb2a6186b5f0c93020d804c833</originalsourceid><addsrcrecordid>eNpVkVtrGzEQhUVoaW79C0FvbSDeji6r1VJoCcZpCgl5SNpXoZVkW2UtGUl28Et-e3ZJYtKnGTgz3wznIPSFQEUlNN9ILWDStKSpZvcVBdJWlFcMKiIBRFsfoKP9xId3_SE6zvkfAGfQ0k_okBEmRt4RerqNqejelx1OuriM9SqGBfbB-q23G91nbL1ehJidxY--LPHSrXXxxWc8xVufNhl_vZ7-Pf-OdcCxyy5tBzkG3WMTlwMc57Kxuws8C4teB3uBKYDEJQ6ViFP0cT7ccJ9f6wn6czV7mF5Pbu5-_Z5e3kwM56RMCO84EwY60UrrLGuF7QCc4aTTgjVQ19zIeWM6qgWRoqvnYFoGFKyEQWHsBP144a433cpZ40JJulfr5Fc67VTUXv2vBL9Ui7hVQghJpRwAP18AJsWck5vvdwmo0Uo1mq1Gs9XsXo3RKMoVA_UazUA4e__Cfv8tC_YMmSeMLw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Mortality rates among individuals diagnosed with hepatitis C virus (HCV); an observational cohort study, England, 2008 to 2016</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Ireland, Georgina ; Mandal, Sema ; Hickman, Matthew ; Ramsay, Mary ; Harris, Ross ; Simmons, Ruth</creator><creatorcontrib>Ireland, Georgina ; Mandal, Sema ; Hickman, Matthew ; Ramsay, Mary ; Harris, Ross ; Simmons, Ruth</creatorcontrib><description>BackgroundMonitoring trends in mortality for individuals diagnosed with hepatitis C virus (HCV) infection are important as we expand treatment and move towards World Health Organization elimination targets.AimTo estimate mortality rates for individuals aged ≥ 15 years diagnosed with HCV infection in England 2008-16.MethodsAn observational cohort study whereby death certificate information was linked to the Sentinel Surveillance of Blood Borne Virus Testing in England. Age-sex standardised mortality rates (ASMR) for individuals diagnosed with HCV infection (2008-16) were calculated and compared to the general population.ResultsOf 43,895 individuals with HCV infection, 2,656 (6.3%) died. All-cause ASMRs were 2,834.2 per 100,000 person years (PY), 2.3 times higher than in the general population. In individuals aged 30-69 years, all-cause mortality rates were 1,768.9 per 100,000 PY among individuals with HCV, 4.7 times higher than in the general population. ASMRs had not decreased between 2010 (2,992) and 2016 (2,340; p=0.10), with no change from 2014 (p = 0.058). ASMRs were 441.0 times higher for hepatitis, 34.4 times higher for liver cancer, 8.1 times higher for end stage liver disease and 6.4 times higher for external causes than in the general population.ConclusionsMortality was higher in individuals with diagnosed HCV infection compared to the general population, highlighting health inequalities. There is a need to improve HCV diagnosis, engagement in care and treatment rates. The high mortality from external causes highlights the importance of integrated health and social care strategies and addressing the needs of this vulnerable population.</description><identifier>ISSN: 1560-7917</identifier><identifier>ISSN: 1025-496X</identifier><identifier>EISSN: 1560-7917</identifier><identifier>DOI: 10.2807/1560-7917.ES.2019.24.30.1800695</identifier><identifier>PMID: 31362807</identifier><language>eng</language><publisher>Sweden: European Centre for Disease Prevention and Control (ECDC)</publisher><subject>Adolescent ; Adult ; Aged ; Antiviral Agents - administration &amp; dosage ; Antiviral Agents - therapeutic use ; Cause of Death ; Cohort Studies ; End Stage Liver Disease - complications ; End Stage Liver Disease - mortality ; England - epidemiology ; Female ; Hepacivirus - isolation &amp; purification ; Hepatitis C - diagnosis ; Hepatitis C - drug therapy ; Hepatitis C - mortality ; Humans ; Liver Diseases, Alcoholic - complications ; Liver Diseases, Alcoholic - mortality ; Liver Neoplasms - complications ; Liver Neoplasms - mortality ; Male ; Middle Aged ; Mortality - trends ; Non-alcoholic Fatty Liver Disease - complications ; Non-alcoholic Fatty Liver Disease - mortality ; Sentinel Surveillance ; Young Adult</subject><ispartof>Euro surveillance : bulletin européen sur les maladies transmissibles, 2019-07, Vol.24 (30)</ispartof><rights>This article is copyright of the authors or their affiliated institutions, 2019. 2019 The authors or their affiliated institutions</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-14b436c0b698ded396db00ec41ba6370554c8f7cb2a6186b5f0c93020d804c833</citedby><cites>FETCH-LOGICAL-c441t-14b436c0b698ded396db00ec41ba6370554c8f7cb2a6186b5f0c93020d804c833</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668288/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668288/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31362807$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ireland, Georgina</creatorcontrib><creatorcontrib>Mandal, Sema</creatorcontrib><creatorcontrib>Hickman, Matthew</creatorcontrib><creatorcontrib>Ramsay, Mary</creatorcontrib><creatorcontrib>Harris, Ross</creatorcontrib><creatorcontrib>Simmons, Ruth</creatorcontrib><title>Mortality rates among individuals diagnosed with hepatitis C virus (HCV); an observational cohort study, England, 2008 to 2016</title><title>Euro surveillance : bulletin européen sur les maladies transmissibles</title><addtitle>Euro Surveill</addtitle><description>BackgroundMonitoring trends in mortality for individuals diagnosed with hepatitis C virus (HCV) infection are important as we expand treatment and move towards World Health Organization elimination targets.AimTo estimate mortality rates for individuals aged ≥ 15 years diagnosed with HCV infection in England 2008-16.MethodsAn observational cohort study whereby death certificate information was linked to the Sentinel Surveillance of Blood Borne Virus Testing in England. Age-sex standardised mortality rates (ASMR) for individuals diagnosed with HCV infection (2008-16) were calculated and compared to the general population.ResultsOf 43,895 individuals with HCV infection, 2,656 (6.3%) died. All-cause ASMRs were 2,834.2 per 100,000 person years (PY), 2.3 times higher than in the general population. In individuals aged 30-69 years, all-cause mortality rates were 1,768.9 per 100,000 PY among individuals with HCV, 4.7 times higher than in the general population. ASMRs had not decreased between 2010 (2,992) and 2016 (2,340; p=0.10), with no change from 2014 (p = 0.058). ASMRs were 441.0 times higher for hepatitis, 34.4 times higher for liver cancer, 8.1 times higher for end stage liver disease and 6.4 times higher for external causes than in the general population.ConclusionsMortality was higher in individuals with diagnosed HCV infection compared to the general population, highlighting health inequalities. There is a need to improve HCV diagnosis, engagement in care and treatment rates. The high mortality from external causes highlights the importance of integrated health and social care strategies and addressing the needs of this vulnerable population.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antiviral Agents - administration &amp; dosage</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Cause of Death</subject><subject>Cohort Studies</subject><subject>End Stage Liver Disease - complications</subject><subject>End Stage Liver Disease - mortality</subject><subject>England - epidemiology</subject><subject>Female</subject><subject>Hepacivirus - isolation &amp; purification</subject><subject>Hepatitis C - diagnosis</subject><subject>Hepatitis C - drug therapy</subject><subject>Hepatitis C - mortality</subject><subject>Humans</subject><subject>Liver Diseases, Alcoholic - complications</subject><subject>Liver Diseases, Alcoholic - mortality</subject><subject>Liver Neoplasms - complications</subject><subject>Liver Neoplasms - mortality</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mortality - trends</subject><subject>Non-alcoholic Fatty Liver Disease - complications</subject><subject>Non-alcoholic Fatty Liver Disease - mortality</subject><subject>Sentinel Surveillance</subject><subject>Young Adult</subject><issn>1560-7917</issn><issn>1025-496X</issn><issn>1560-7917</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkVtrGzEQhUVoaW79C0FvbSDeji6r1VJoCcZpCgl5SNpXoZVkW2UtGUl28Et-e3ZJYtKnGTgz3wznIPSFQEUlNN9ILWDStKSpZvcVBdJWlFcMKiIBRFsfoKP9xId3_SE6zvkfAGfQ0k_okBEmRt4RerqNqejelx1OuriM9SqGBfbB-q23G91nbL1ehJidxY--LPHSrXXxxWc8xVufNhl_vZ7-Pf-OdcCxyy5tBzkG3WMTlwMc57Kxuws8C4teB3uBKYDEJQ6ViFP0cT7ccJ9f6wn6czV7mF5Pbu5-_Z5e3kwM56RMCO84EwY60UrrLGuF7QCc4aTTgjVQ19zIeWM6qgWRoqvnYFoGFKyEQWHsBP144a433cpZ40JJulfr5Fc67VTUXv2vBL9Ui7hVQghJpRwAP18AJsWck5vvdwmo0Uo1mq1Gs9XsXo3RKMoVA_UazUA4e__Cfv8tC_YMmSeMLw</recordid><startdate>20190725</startdate><enddate>20190725</enddate><creator>Ireland, Georgina</creator><creator>Mandal, Sema</creator><creator>Hickman, Matthew</creator><creator>Ramsay, Mary</creator><creator>Harris, Ross</creator><creator>Simmons, Ruth</creator><general>European Centre for Disease Prevention and Control (ECDC)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20190725</creationdate><title>Mortality rates among individuals diagnosed with hepatitis C virus (HCV); an observational cohort study, England, 2008 to 2016</title><author>Ireland, Georgina ; Mandal, Sema ; Hickman, Matthew ; Ramsay, Mary ; Harris, Ross ; Simmons, Ruth</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-14b436c0b698ded396db00ec41ba6370554c8f7cb2a6186b5f0c93020d804c833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antiviral Agents - administration &amp; dosage</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Cause of Death</topic><topic>Cohort Studies</topic><topic>End Stage Liver Disease - complications</topic><topic>End Stage Liver Disease - mortality</topic><topic>England - epidemiology</topic><topic>Female</topic><topic>Hepacivirus - isolation &amp; purification</topic><topic>Hepatitis C - diagnosis</topic><topic>Hepatitis C - drug therapy</topic><topic>Hepatitis C - mortality</topic><topic>Humans</topic><topic>Liver Diseases, Alcoholic - complications</topic><topic>Liver Diseases, Alcoholic - mortality</topic><topic>Liver Neoplasms - complications</topic><topic>Liver Neoplasms - mortality</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mortality - trends</topic><topic>Non-alcoholic Fatty Liver Disease - complications</topic><topic>Non-alcoholic Fatty Liver Disease - mortality</topic><topic>Sentinel Surveillance</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ireland, Georgina</creatorcontrib><creatorcontrib>Mandal, Sema</creatorcontrib><creatorcontrib>Hickman, Matthew</creatorcontrib><creatorcontrib>Ramsay, Mary</creatorcontrib><creatorcontrib>Harris, Ross</creatorcontrib><creatorcontrib>Simmons, Ruth</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Euro surveillance : bulletin européen sur les maladies transmissibles</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ireland, Georgina</au><au>Mandal, Sema</au><au>Hickman, Matthew</au><au>Ramsay, Mary</au><au>Harris, Ross</au><au>Simmons, Ruth</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mortality rates among individuals diagnosed with hepatitis C virus (HCV); an observational cohort study, England, 2008 to 2016</atitle><jtitle>Euro surveillance : bulletin européen sur les maladies transmissibles</jtitle><addtitle>Euro Surveill</addtitle><date>2019-07-25</date><risdate>2019</risdate><volume>24</volume><issue>30</issue><issn>1560-7917</issn><issn>1025-496X</issn><eissn>1560-7917</eissn><abstract>BackgroundMonitoring trends in mortality for individuals diagnosed with hepatitis C virus (HCV) infection are important as we expand treatment and move towards World Health Organization elimination targets.AimTo estimate mortality rates for individuals aged ≥ 15 years diagnosed with HCV infection in England 2008-16.MethodsAn observational cohort study whereby death certificate information was linked to the Sentinel Surveillance of Blood Borne Virus Testing in England. Age-sex standardised mortality rates (ASMR) for individuals diagnosed with HCV infection (2008-16) were calculated and compared to the general population.ResultsOf 43,895 individuals with HCV infection, 2,656 (6.3%) died. All-cause ASMRs were 2,834.2 per 100,000 person years (PY), 2.3 times higher than in the general population. In individuals aged 30-69 years, all-cause mortality rates were 1,768.9 per 100,000 PY among individuals with HCV, 4.7 times higher than in the general population. ASMRs had not decreased between 2010 (2,992) and 2016 (2,340; p=0.10), with no change from 2014 (p = 0.058). ASMRs were 441.0 times higher for hepatitis, 34.4 times higher for liver cancer, 8.1 times higher for end stage liver disease and 6.4 times higher for external causes than in the general population.ConclusionsMortality was higher in individuals with diagnosed HCV infection compared to the general population, highlighting health inequalities. There is a need to improve HCV diagnosis, engagement in care and treatment rates. The high mortality from external causes highlights the importance of integrated health and social care strategies and addressing the needs of this vulnerable population.</abstract><cop>Sweden</cop><pub>European Centre for Disease Prevention and Control (ECDC)</pub><pmid>31362807</pmid><doi>10.2807/1560-7917.ES.2019.24.30.1800695</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1560-7917
ispartof Euro surveillance : bulletin européen sur les maladies transmissibles, 2019-07, Vol.24 (30)
issn 1560-7917
1025-496X
1560-7917
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6668288
source MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Adolescent
Adult
Aged
Antiviral Agents - administration & dosage
Antiviral Agents - therapeutic use
Cause of Death
Cohort Studies
End Stage Liver Disease - complications
End Stage Liver Disease - mortality
England - epidemiology
Female
Hepacivirus - isolation & purification
Hepatitis C - diagnosis
Hepatitis C - drug therapy
Hepatitis C - mortality
Humans
Liver Diseases, Alcoholic - complications
Liver Diseases, Alcoholic - mortality
Liver Neoplasms - complications
Liver Neoplasms - mortality
Male
Middle Aged
Mortality - trends
Non-alcoholic Fatty Liver Disease - complications
Non-alcoholic Fatty Liver Disease - mortality
Sentinel Surveillance
Young Adult
title Mortality rates among individuals diagnosed with hepatitis C virus (HCV); an observational cohort study, England, 2008 to 2016
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T00%3A54%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mortality%20rates%20among%20individuals%20diagnosed%20with%20hepatitis%20C%20virus%20(HCV);%20an%20observational%20cohort%20study,%20England,%202008%20to%202016&rft.jtitle=Euro%20surveillance%20:%20bulletin%20europ%C3%A9en%20sur%20les%20maladies%20transmissibles&rft.au=Ireland,%20Georgina&rft.date=2019-07-25&rft.volume=24&rft.issue=30&rft.issn=1560-7917&rft.eissn=1560-7917&rft_id=info:doi/10.2807/1560-7917.ES.2019.24.30.1800695&rft_dat=%3Cpubmed_cross%3E31362807%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/31362807&rfr_iscdi=true